PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target

Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Erb, Holger Hans Hermann, Ebert, Marlies, Kuhn, Ronja, Donix, Lukas, Haferkamp, Axel, Seed, Robert Ian, Jüngel, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804980/
https://www.ncbi.nlm.nih.gov/pubmed/31639157
http://dx.doi.org/10.1371/journal.pone.0224085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804980/
https://www.ncbi.nlm.nih.gov/pubmed/31639157
http://dx.doi.org/10.1371/journal.pone.0224085

Ejemplares similares